[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"barretts-esophagus-with-or-without-dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:barretts-esophagus-with-or-without-dysplasia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100643087","phase-1-development-of-fluorescent-lectin-tracers-with-dedicated-technology-for-in-vivo-detection-of-esophageal-dysplasia-in-barrett-patients-100643087",false,"NCT07643727","Development of Fluorescent Lectin Tracers With Dedicated Technology for in Vivo Detection of Esophageal Dysplasia in Barrett Patients","Glycan Near-Infrared Imaging Using Fluorescently Labeled Wheat Germ Agglutinin (WGA): Evaluation of Safety and Feasibility in a Prospective Pilot Study","GRAIN","Inclusion Criteria:\n\n* Patients with confirmed Barrett's esophagus, esophageal dysplasia, or superficial esophageal ade-nocarcinoma.\n* Patients scheduled for gastroscopy procedure within the UMCG.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy to wheat.\n* Celiac disease.\n* Dermatitis herpetiformis.\n* Pregnancy or breastfeeding.","ALL","18 Years",{"count":20,"type":21},49,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to evaluate the feasibility of WGA-800CW with dedicated imaging systems for detection of invisible esophageal dysplasia in patients with Barrett's esophagus.\n\nThe main questions it aims to answer are:\n\n* What is the optimal dose of WGA-800CW that maximizes the tumor-to-background ratio and enables clear visualization of the tumor?\n* Can fluorescence endoscopy with WGA-800CW in combination with qFME detect dysplastic esophageal lesions?\n\nIn this non-randomized, non-blinded, prospective, feasibility intervention study, 49 participants with Barrett's esophagus will be included. Patients will undergo the combined procedure (qFME and\u002For OCT-NIRF and HD-WLE). WGA-800CW will be topically administered via a spray catheter during gastroscopy procedures and fluorescent signal will be assessed with qFME and\u002For OCT-NIRF.",[27,28],"Barrett's Esophagus With or Without Dysplasia","Barrett Esophagus Adenocarcinoma",[30,31,32,33,34,35],"Glycan","Oncology","Fluorescent tracers","qFME","First-in-human","Lectin","NOT_YET_RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":21},"2026-06-01",{"date":44,"type":21},"2028-10-31",{"name":46,"class":47},"University Medical Center Groningen","OTHER"]